Phase 3 psilocybin and LSD data plus new FDA guidance fuel a depression boom—yet clinics still wrestle with dosing time, cost, access.
|Slideshows|October 2, 2020
7 Common Mistakes With Antidepressants
Author(s)Chris Aiken, MD
Drug interactions, discontinuation issues, adverse effects, and more. These are the problems that are often overlooked.
Advertisement
Advertisement
Related to this article
Ketamine, esketamine, and ECT can rapidly ease suicidal thoughts, but evidence for preventing attempts or deaths remains limited—see what’s proven.
Helus Pharma advances oral deuterated psilocin HLP003 for MDD, detailing new efficacy and safety analyses plus ongoing phase 3 PARADIGM trial updates.
New real-world studies show Vraylar boosts depression relief, functioning, and quality of life in MDD and bipolar I patients beyond clinical trials.
Advertisement
Advertisement
Trending on Psychiatric Times
1
Real-World Data Link LAI Risperidone to Fewer Emergency Visits in Schizophrenia, Improved Bipolar Treatment
2
Nature vs Nurture: The Interplay Between Genetics and Environmental Influences
3
Psychedelics as a Catalyst for Change: The Evolving Competitive Landscape in Depression
4
The Psychiatric Pipeline in Review: Quarter 3, 2026
5